
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc is noted for its promising collaboration with Gilead, which offers a competitive edge through advanced cell therapy manufacturing and patient support, thereby potentially boosting market position and sales. The anticipated approval of Anito-cel for multiple myeloma patients by the end of 2026 is expected to lead to a highly successful product launch and a robust market presence, with peak global sales projections reaching $7 billion. Furthermore, the management's effective execution in developing Anito-cel and the favorable clinical outcomes compared to existing treatments enhance the company's overall value proposition to shareholders.
Bears say
The analysis indicates that Arcellx Inc. faces significant risks related to its clinical-stage development and potential commercial viability, as evidenced by the downgrade of its shares to Hold based on an acquisition proposal from Gilead Sciences (GILD) valued at $7.8 billion. Concerns about the effectiveness of its D-Domain CAR-T therapy platform and the ARC-SparX platform create uncertainty regarding the generation of successful clinical candidates, which may hinder future growth. Additionally, the company is vulnerable to various risks, including competition, pricing pressures, and regulatory challenges, all of which could severely impact its valuation and stock performance going forward.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares